Myrtle S. Potter, a director at Guardant Health, Inc. (NASDAQ: GH), executed a transaction involving the sale of 1,556 shares of the company's common stock on June 22, 2026. The shares were divested at a price of $131.16 each, resulting in a total transaction value of approximately $204,084. This sale occurs as Guardant Health's stock trades near its 52-week high of $135, following a remarkable 165% gain over the past year. The current stock price of $130.84 suggests the company may be overvalued according to InvestingPro analysis, which places it among the most overvalued stocks in the healthcare sector.
Following this transaction, Ms. Potter directly holds 20,971 shares of Guardant Health common stock. For investors seeking deeper insights into GH's valuation and growth prospects, InvestingPro offers access to 10 additional ProTips and comprehensive Pro Research Reports covering over 1,400 US equities. The sale was reported in a Form 4 filing with the Securities and Exchange Commission.
In other recent news, Guardant Health Inc. has made significant strides with its recent FDA approval for the Guardant360 CDx test. This test serves as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, allowing it to identify patients with specific mutations eligible for treatment. Following this FDA approval, Mizuho raised its price target for Guardant Health to $175, maintaining an Outperform rating. Additionally, the American Cancer Society has included Guardant Health's Shield blood test in its colorectal cancer screening guidelines, further boosting the company's profile.
Analyst firms have shown confidence in Guardant Health, with RBC Capital initiating coverage with an Outperform rating and a price target of $185. Goldman Sachs also began coverage with a Buy rating and a $165 price target, highlighting growth drivers such as the FDA-approved G360 CDx 740-gene panel and the upcoming launch of a tumor-informed minimal residual disease test. Wolfe Research has also initiated coverage with an Outperform rating, setting a price target of $150. These developments indicate a positive outlook from analysts on Guardant Health's growth potential.